Sort   by:  
 Page size 
TranscriptomicsHTG EdgeSeq analysis of parental and CDK4/6i-resistant (Ribociclib or Palbociclib) T47D breast cancer cell clones
Do illuminate the vulnerabilities of CDK4/6i-resistant T47D breast cancer cells, we created CDK4/6i-resistant T47D cell clones through a gradual dose escalation protocol using the selective CDK4/6 inhibitors Ribociclib and Palbociclib. We then performed gene expression analysis targeting 2549 genes ...
ORGANISM(S): Homo sapiens 
2026-06-17 | E-MTAB-15265 | biostudies-arrayexpress
MetabolomicsTargeting PI3K inhibitor resistance in breast cancer with metabolic drugs

Activating PIK3CA mutations, present in up to 40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (Her2-) breast cancer (BC) patients, can be effectively targeted with the alpha isoform-specific PI3K inhibitor Alpelisib. This treatment significantly improves ...

2026-08-21 | MTBLS11671 | MetaboLights
Sort   by:  
 Page size